Plus Therapeutics Inc. (NASDAQ: PSTV) stock gained by 0.52% at last close while the PSTV stock price surges by 12.37% in the pre-market trading session. Plus Therapeutics is a medical pharmaceutical company whose radiotherapeutic portfolio is focused on nanoliposome-encapsulated radionuclides for a variety of cancer targets.
PSTV stock’ Significant Development
Plus Therapeutics published findings from the ReSPECT Phase 1 clinical study, which was funded by the National Institutes of Health and looked at its primary experimental medication, Rhenium-186 NanoLiposome (186RNL), in recurrent glioblastoma (GBM). The research found that administering 186RNL at substantially greater doses than traditional treatment methods such as external beam radiation therapy was well tolerated in adult patients with recurrent GBM. It’s made to deliver targeted beta radiation to the tumor through convection-enhanced delivery with little exposure to nearby tissues.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
This research will be presented as an E-Poster video at the 2021 American Association of Neurological Surgeons Annual Scientific Meeting which has started from August 21 and will continue till August 25, 2021.
Michael G. DeCuypere, FAANS, Northwestern University Feinberg School of Medicine, and presenter of the E-Poster stated,
The ReSPECTTM study illustrates how 186RNL may safely, efficiently, and easily administer a high dose of radiation directly to adult brain tumors. Children with brain tumors have few alternatives, and 186RNL given through a less invasive technique might be a valuable new treatment option for them.
Additional significant outcomes from the ReSPECT clinical study for recurrent GBM in adults include:
- When coverage was 75 percent or more (n=10), the mean dosage of 186RNL was 392 Gy (CI 306 – 478).
- The therapy was well tolerated, with no dose-limiting toxicity or major adverse events reported by the participants (n=18).
Marc Hedrick, President, and CEO of PSTV stock commented,
They are excited to investigate the usage of 186RNL in children with diverse types of pediatric brain tumors. Dr. DeCuypere and his colleagues at Chicago’s Lurie Children’s Hospital have been excellent academic collaborators, and they are ideally positioned to move RNL ahead quickly to address these difficult issues in children.